key: cord-0776055-7i31ghpb
authors: Chen, Linzhe; Zhang, Guoliang; Liu, Longqi; Li, Zida
title: Emerging biosensing technologies for improved diagnostics of COVID-19 and future pandemics
date: 2020-12-13
journal: Talanta
DOI: 10.1016/j.talanta.2020.121986
sha: 6b2495220e9bac40a5ae7558b722e5f8a7181522
doc_id: 776055
cord_uid: 7i31ghpb

Diagnostic tools play significant roles in the fight against COVID-19 and other pandemics. Existing tests, such as RT-qPCR, have limitations including long assay time, low throughput, inadequate sensitivity, and suboptimal portability. Emerging biosensing technologies hold the promise to develop tests that are rapid, highly sensitive, and suitable for point-of-care testing, which could significantly facilitate the testing of COVID-19. Despite that, practical applications of such biosensors in pandemics have yet to be achieved. In this review, we consolidate the newly developed diagnostic tools for COVID-19 using emerging biosensing technologies and discuss their application promise. In particular, we present nucleic acid tests and antibody tests of COVID-19 based on both conventional and emerging biosensing methods. We then provide perspectives on the existing challenges and potential solutions.

SARS-CoV-2 carriers is extremely important, requiring sensitive tests which can be offered in high volume. Secondly, it is increasingly believed that COVID-19 will not disappear within a year. To re-open the economy and resume normal life safely, it is important to have virus and antibody tests to keep track of infections and immunity. [8] Two types of tests have been developed for the diagnostics of COVID-19, namely nucleic acid test and antibody test. After initial virus infection, patients normally experience an incubation period of 4-5 days on average, when virus replicates and viral load increases. [9] Viral load usually reaches a peak in the second week after symptom onsets, before it gradually winds down, as shown in Fig. 2 . [10] Given the quick response of viral load to virus infection, test of the viral nucleic acid has been the primary means for the confirmation of infection. In contrast, antibody load shows a much slower response. It was reported that on average, IgM and IgG did not reach a detectable level until 13 days after symptom onset (Fig. 2 ). [11, 12] However, antibody in the serum stays at a relatively high level even after recovery. Therefore, antibody test has been prescribed for the identification of infection history and existing immunity.

The nucleic acid test of COVID-19 has been predominantly based on quantitative reverse-transcription polymerase chain reaction (RT-qPCR), which detects the presence of virus during the process of amplifying certain genes of the virus. Despite its wide use, RT-qPCR has a few limitations. Firstly, the diagnosis of early-phase infection, where the viral load is very low [13] , is normally ineffective, leading to false negatives. Secondly, the testing throughput needs to be improved given the rapid increase in suspected cases before the curve is flattened. Thirdly, RT-qPCR cannot be easily adapted for point-of-care testing. In less developed areas, where life is impacted the most by the pandemic, testing laboratories are normally lacking, limiting the testing capability and timely case identification. In addition, in settings such as J o u r n a l P r e -p r o o f customs, resorting to laboratories for testing is impractical. In both scenarios, it is preferable to have the testing performed on-site without being sent to central laboratory. Ideally, such tests should require minimal human intervention for biosafety concerns and generate results in several minutes.

Biosensing is a research field that has seen rapid development in the past decade.

Leveraging advances in microfabrication, nanotechnology, and novel biotechnology, researchers have developed biosensors with improved sensitivity, specificity, testing speed, and cost-effectivity. [14] As such, emerging biosensing technologies hold great promise to develop tests that could potentially address the limitations of existing tests.

[15, 16] Indeed, in face of COVID-19 pandemic, several diagnostic tests based on emerging biosensing technologies have been quickly developed, enabling sensitive, high-throughput, and point-of-care testing. Available diagnostic tools for have been summarized in a few reviews, including those focused on polymerase chain reaction, [17] molecular diagnosis, [18, 19] FDA-approved tests, [20] micro-and nanosystems, [21, 22] among others [23] [24] [25] [26] [27] [28] [29] [30] . Nevertheless, reviews focusing on the biosensing perspective have been lacking.

[31] Such reviews would place biosensing research in a pandemic context and provide reflections on how biosensing technologies can better assist infection tests in pandemics. Here, we consolidate the newly developed diagnostic tools for COVID-19 using emerging biosensing technologies and discuss their application promise. We first present COVID-19 tests, including both nucleic acid tests and antibody tests, based on conventional methods and discuss their limitations, before we present the recently developed tests based on emerging biosensors. We further provide comments on the advantages of emerging biosensing technologies as well as the issues that need to be solved to make them more useful in pandemics. We envision the rapid advances in biosensing technology will effectively assist the battle against COVID-19 and future pandemic outbreaks.

J o u r n a l P r e -p r o o f Quantitative reverse-transcription polymerase chain reaction (RT-qPCR) is currently the routine method used for the detection of SARS-CoV-2. Briefly, specimens are collected from patients through nasopharyngeal swab, before the virus RNA is extracted from the medium (Fig. 3) . Virus RNA is then reverse transcribed into complementary DNA, which is in turn amplified through PCR and detected using fluorescent dyes or labeled probe methods. In the PCR process, specifically designed primers are used to ensure that only chosen genes are amplified. Thus, primer design is critical to achieve high sensitivity and specificity. The two assays generated same results on 102 out of 103 specimens, showing an agreement of 99%. However, Ct values from Cepheid assays were slightly lower, which was presumably due to the difference in primer sequences.

RT-qPCR detects nucleic acid sequences regardless of the infectivity of the virus. As such, recovered patients continued to show positive RT-qPCR results, even though replication-competent virus was not isolated. [37, 38] This finding was possibly attributed to that RT-qPCR detected inactive virus remaining in the patients. In the current form of RT-qPCR test for COVID-19, specimen is normally collected by J o u r n a l P r e -p r o o f nasopharyngeal swab, which requires well-trained personnel for reliable sampling.

Specimen collection with compromised quality has been postulated as a potential source of false negative test results. [39] In addition, the high-volume consumption of swabs and transportation medium have brought about supply chain issues. To address this problem, a few methods have been reported. Srivatsan et al. proposed a simplified protocol for RT-qPCR tests which perform tests on the swab directly without using transport medium or performing RNA extraction, aiming to reduce the pressure on test-related consumable supply. Results showed that dry swabs supported the virus detection at the endpoint of RT-qPCR and the sensitivity was not substantially compromised. Given the technical difficulty in obtaining nasopharyngeal swab specimen, the possibility of using alternative specimen have been explored.

Researchers reported the detection of virus using saliva specimen with high sensitivity and high agreement in testing outcome with the established test protocols, suggesting that saliva could be a reliable specimen for case confirmation. [40, 41] 

Though RT-qPCR has good sensitivity and specificity, it requires dedicated instruments in a central laboratory, resulting in turnaround time of normally more than one day. In addition, the limit of detection and the accuracy of the quantitative measurement can be inadequate for early detections. In this regard, a few new nucleic acid sensing technologies can serve as great alternatives.

Digital PCR (dPCR) utilizes tens of thousands of tiny compartments, such as droplets or microwells, and performs PCR in each compartment (Fig. 4a) [42] The primers and probes adopted in the ddPCR also targeted the ORF1ab and N gene as commonly done in RT-qPCR. Results showed that the ddPCR had a lower limit of detection of 0.109 copies/µL and 0.021 copies/µL for ORF1ab and N genes, respectively, which were more than 500 times lower than that of most RT-qPCR tests.

The overall accuracy was 94.3%, and the test was able to identify 92.6% of the false negatives from RT-qPCR. Similar works using ddPCR was also reported by other groups. [43] [44] [45] In addition, instead of droplets, microwells had been implemented for dPCR assay of SARS-CoV-2, and the assay has obtained EUA from the US FDA. [46] Despite the improved quantification in measurement, a few limitations remain in dPCR. For example, the dynamic range of dPCR depends on the amount of partitions that can be generated, and with the current dPCR technologies, the dynamic range is generally lower than qPCR. In terms of operation, dPCR have lower throughput and requires specialized consumables, increasing the cost per test. [47] In addition, an inherent limitation of PCR-based methods is that PCR requires cyclic heating, which compromises the amplification efficiency and complicates the instruments, making it not ideal for point-of-care diagnosis. In contrast, isothermal amplifications are performed at constant temperature with rapid reaction and simplified instruments. The lowered demand on the instruments makes it easily adoptable for tests outside of central laboratories, which would significantly boost testing efficiency. gene and N gene and tested them using synthetic RNAs. Testing results had 100% agreement with RT-qPCR, and an analytical sensitivity of 4.8 copies/µL was achieved.

In addition, tests using crude cell lysates without RNA extraction also showed similar sensitivity, suggesting that RT-LAMP has the potential to serve as a point-of-care assay for field application.

In another study, Rabe et al. developed similar RT-LAMP assays and optimized virus inactivation and purification protocols. [49] The optimized assay was able to be completed in 30 minutes, and the analytical sensitivity was 1 copy/µL following the purification protocol. Impressively, the sample inactivation and purification process did not require commercial reagent kits, and the overall cost was only 0.07 US dollars per sample, making it affordable for massive testing. Similar works have also been reported by other research groups. [50] [51] [52] [53] [54] [55] Though LAMP is a convenient technique for nucleic acid amplification, a few limitations shall be addressed to achieve widespread adoption. First, LAMP uses a set of four or six primers, making primer designs subject to more constraint and difficult to implement in certain settings. [56] Second, multiplex detection using LAMP is less developed than using PCR, since larger number of primers imposes greater chance of primer-primer interference. Cas12b was also reported. [61] Instead of cleaving ssDNA, Cas13 cleaves single-stranded RNA and has also been adapted for virus detection. Myhrvold et al. developed a Cas13-based virus detection platform, named specific high-sensitivity enzymatic reporter unlocking (SHERLOCK), and incorporated the biosensing technology into lateral flow assays.

[62] Using SHERLOCK, Dengue and Zika virus were successfully tested in a rapid, quantitative, and portable fashion. Since the outbreak of COVID-19, the same groups quickly developed an assay protocol to detect SARS-CoV-2 along with other respiratory viral pathogens simultaneously, which could potentially enable fast surveillance of circulating viruses. [63] Using synthetic SARS-CoV-2 RNA as the test sample, an analytical sensitivity of 10 copies/µL was demonstrated. Similar

Cas13-based SARS-CoV-2 assays were also achieved by different groups. [64, 65] A shortcoming of CRISPR-based biosensors is that they require protospacer-adjacent motif (PAM) sequences adjacent to the target sequence, which could pose a challenge when performing single nucleotide polymorphism (SNP) discrimination or detection of short sequences. [59] In addition, current CRISPR-based biosensors require amplification and detection in different tubes, complicating the operation and increasing the chance of contamination. Joung et al. developed an optimal combination of LAMP primers and gRNAs to allow for amplification and CRISPR-mediated detection in a single-step reaction, in an assay named SHERLOCK-Testing in One Pot for COVID-19 (STOPCovid). [66, 67] The assay only required micropipettes and 60 ºC water bath, which greatly increased its accessibility. The limit of detection was shown as 100 copies, and the assay could be accomplished within 70 min on a lateral flow assay, making it a powerful tool for point-of-care testing.

It is noteworthy that recently CRISPR-Cas system has also been adopted to develop a massively multiplexed virus detection platform. Coinfection with microorganisms other than SARS-CoV-2 have likely contributed to the morbidity and mortality of COVID-19. To detect SARS-CoV-2 while simultaneously assessing the background microbiome, nanopore sequencing was used to perform metagenomic analysis. [73] Results identified the coinfection with other microorganisms such as Fusobacterium periodonticum and human betaherpes virus 5 among patients. Though in terms of diagnosis, the sensitivity is not as good as RT-qPCR, this method can potentially be used to guide coinfection treatment and monitor viral evolution. A nanopore sequencing based protocol for the molecular diagnosis of COVID-19 was later published by Oxford Nanopore Technogies Inc. and have been widely adopted in the United Kingdom. [74, 75] In addition, a few other sequencing-based SARS-CoV-2 detection and surveillance methods have been reported. Chandler-Brown et al. developed a protocol based on Sanger sequencing. [76] Briefly, specimen was directly added to PCR master mix without the step of RNA extraction, before being amplified and sequenced. Using frame-shifted spike-in as the specimen, it was shown that a limit of detection Localized surface plasmon resonance (LSPR) sensing uses metal nanoparticles, commonly gold, to localize surface plasmon and enhance the peak signal in the absorption spectrum, making it a sensitive biomolecule detection technology. Efforts have been devoted to develop LSPR-based biosensors for the detection of a wide range of substances. [80, 81] Recently, LSPR has been adapted to develop an assay for the detection of SARS-CoV-2 nucleic acid. [82] DNA complementary to RdRp sequence was linked to the surface of gold nano-island, and its hybridization with RdRp sequence led to a shift in the detected spectrum, which was subsequently used J o u r n a l P r e -p r o o f to calculated the virus concentration. In addition to LSPR, plasmonic photothermal effect was utilized to implement localized heating, which reduced the hybridization between mismatched oligonucleotides and increased detection accuracy. Using synthetic RdRp sequence, it was shown that a detection limit of 0.22 pM (~1.32×10 5 copies/µL) was achieved with good specificity. Since LSPR required dedicated optics and instruments for signal acquisition, further efforts may be necessary to miniaturize the test before it can be applied in the field. In another work, thiol-modified oligonucleotides were used to functionalize gold nanoparticles and allow for agglomeration upon hybridization with target RNA sequence of SARS-CoV-2. [83] This method resulted in a colorimetric assay, which eliminated the need of sophisticated instruments, though the sensitivity was inevitably compromised compared to spectrum-based measurement. In addition to measurements using synthetic oligonucleotides, measurements using clinical samples may also be necessary to further validate the assay.

Antibody test provides important serological information and can serve as a supplement to nucleic acid test. First, it assists contact tracing after a suspected infection by showing whether antibody is present in the serum. [84] Second, it helps reveal the population of asymptomatic cases to facilitate epidemiological study and public health policy making, considering that pre-symptomatic or asymptomatic transmission could happen.

[85] Third, antibody profiles of participants in treatment or vaccine trials provides important information on immune status for the result analysis.

[86] Therefore, developing reliable antibody test is of great importance. S protein, particularly the receptor binding domain (RBD), is thought to be highly antigenic and has been predominantly used as the antigen for antibody capturing. In addition, N protein has also been used in some tests. Based on these antigens, a few antibody tests have been developed, including both conventional assays and assays J o u r n a l P r e -p r o o f based on novel biosensing technologies. Since antibody tests are generally based on specific binding between antigen and antibody, antigen detection can also be achieved using similar detection scheme.

The detection is based on specific binding of antibody and subsequent enzyme reaction, which generates a colorimetric readout. Briefly, a surface, such as a cell plate, is coated with antigen to capture target antibody in the sample, as shown in Fig.   8a . Afterwards, an enzyme-linked antibody binds to the target antibody, which enables the subsequent chromatic reaction. Since the outbreak of COVID-19, several ELISA The authors also showed that the test performances varied depending on the infection stage, and the specificity spanned from 84.3% to 100% in negative controls (pre-COVID-19 specimens). Therefore, detailed serological characterization covering the full spectrum of infections would be required to guide result interpretation.

laboratories for high throughput immunoassays. The testing principle is similar as ELISA, but instead of using enzyme reaction, CLIA uses chemiluminescence to generate light for signal detection. Since the outbreak, several commercial CLIA test kits have been quickly developed. However, due to the short validation time, it was observed that many assays have inadequate or unverified performance. [95, 96] J o u r n a l P r e -p r o o f Therefore, a few groups took the initiative and evaluated the commercial CLIA test kits. For example, Padoan et al. assessed the performance of the SARS-CoV-2 IgM and IgG CLIA kits produced by Snibe (Snibe Co., Ltd., Shenzhen, China). [97] Results showed that imprecision and repeatability was acceptable and the detection of IgG at day 12 had a sensitivity of 100%. In another study, Bryan et al. evaluated the performance of Abbott SARS-CoV-2 IgG test kits on Abbott Architect (Abbott Laboratories, Illinois, US), and results showed a specificity and sensitivity of 99.9% and 100%, respectively. [96] Performance evaluation on other IgG and IgM test kits were also reported. [98, 99] These testing results demonstrated the validity of these CLIA test kits on the market and showed that these CLIA tests could facilitate the serological study of COVID-19.

In addition to these conventional methods, a few antibody assays based on emerging biosensing technologies have been reported as well. These assays are fast and highly sensitive and hold great potential for rapid diagnosis. µg/mL. The assay could be performed in 15 minutes using a portable SPR instrument, making it a possible method for rapid point-of-care testing. A potential limitation is the cost of the assay. The assay required SPR surface for antibody immobilization and SPR instrument for signal detection, which added up to higher cost compared to conventional assays such as ELISA and LFA. In addition, further validation experiments may be necessary to improve the test reliability.

Microfluidics is a technology that manipulates fluids in microscale with high surface-to-volume ratio, which enables miniaturized assays for fast and sensitive detection with reduced sample consumption. Tan et al. developed a microfluidic ELISA system using capillary tubes as the immobilizing surface (Fig. 9b) . The small diameters of the capillaries facilitated rapid reaction and reduced sample consumption.

Consequently, the ELISA assay could be completed within 30 min using only a few microliters of samples.

[103] Using the same platform, assays for the detection of SARS-CoV-2 specific IgG and S protein was developed.

[104] The adapted assays coated S1 protein on the capillary wall to capture IgG; alternatively, SARS-CoV-2 antibody was coated to capture S protein in the serum sample. The developed assays took only 15-20 min and consumed only 10 µL serum for each test, and the lower limit of detection of SRAS-CoV-2 S1 protein was 0. Compared to antibodies, aptamers have advantages such as smaller size, better stability, easy synthesis, and better quality control. The first step towards the development of aptamer-based assay for the detection of SARS-CoV-2 is the identification of aptamer sequence. To this end, Song et al. used an ACE2 competition based aptamer selection strategy and identified a 51-base hairpin-structured aptamer and a 67-base aptamer, targeting the RBD of SARS-CoV-2 (Fig. 10b) . [107] High-binding affinity was demonstrated, with K d values of 5.8 nM and 19.9 nM, respectively. These developed aptamers can potentially be used to develop new COVID-19 diagnostic tools.

Pandemic is a major threat that challenges global health and economic stability, and it is generally agreed by the public health experts that pandemics will keep occurring.

[108] When an outbreak does occur, it is extremely important to have effective diagnostic tools that can be deployed in a matter of weeks or even days. Conventional testing methods, such as RT-qPCR, ELISA, and colloidal gold-based lateral flow assays, have shown limitations such as suboptimal sensitivity, throughput, and portability. Biosensing technologies based on nanomaterials and microfluidics have made great progress in the past a few years, bringing about emerging biosensors that are fast, portable, and highly sensitive with minimal sample consumptions.

Nevertheless, very few novel biosensors have practically contributed to the testing so far in the COVID-19 pandemic. Two issues could have contributed to this situation.

The first issue lies in the facilities required for emerging biosensing technologies.

Most new biosensing technologies require dedicated instrumentation facilities, such as laser, spectrometers, or source-measure units, the installation and calibration of which are costly both time and finance wise. In pandemics, when time is critically important, J o u r n a l P r e -p r o o f tests that can be performed on the existing facilities are highly favorable. For example, if a new test can be adapted and performed on high throughput automated in vitro diagnostics systems, such as Abbott Architect and Roche cobas, it would be more actionable to incorporate this test in the clinical laboratory. As for point-of-care testing, lateral flow assay is commonly used, and the main "facility" is the dipstick, which is commercially available. As such, a new test which can be implemented on lateral flow assay would have a better chance to be adopted.

Another issue is related to the test reproducibility and reliability. Despite that many emerging biosensors have shown superior sensitivity and lower limit of detection, due to their immature nature, most of them suffer from high testing variance and suboptimal reliability, which prevent them from being admitted to clinical settings.

Before they can be widely accepted, tests might have to go through iterations of troubleshooting in order to meet the validation and verification requirements. The long troubleshooting process stops them from being prioritized in pandemics.

Therefore, biosensing research should consider the compatibility with existing testing infrastructures, as well as repeatability and reliability, so that these biosensors can be readily applicable in pandemics. Antibody level is presented as the ratio of measured values to cutoff value. Dynamic tracings were compiled based on data from [9] [10] [11] , and infectiousness was compiled based on data from [109] .

J o u r n a l P r e -p r o o f 

World Health Organization, Coronavirus disease (COVID-19) Situation Report-108

A new coronavirus associated with human respiratory disease in China

SnapShot: COVID-19

US Centers for Disease Control and Prevention. Person-to-person spread

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

COVID-19, SARS and MERS: are they closely related? Clinical Microbiology and Infection

Presumed Asymptomatic Carrier Transmission of COVID-19

National Institute of Allergy and Infectious Disease, NIAID Strategic Plan for COVID-19 Research

The Incubation Period of Coronavirus Disease

From Publicly Reported Confirmed Cases: Estimation and Application

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Antibody responses to SARS-CoV-2 in patients with COVID-19

Patterns of IgG and IgM antibody response in COVID-19 patients. Emerging Microbes & Infections, 2020

Viral load quantitation of SARS-coronavirus RNA using a one-step real-time RT-PCR

Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection

Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape

Fighting COVID-19: Integrated Micro-and Nanosystems for Viral Infection Diagnostics

Clinically practiced and commercially viable nanobio engineered analytical methods for COVID-19 diagnosis

Current and Perspective Diagnostic Techniques for COVID-19

Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. Viruses

Diagnosing COVID-19: The Disease and Tools for Detection

Detecting the Coronavirus (COVID-19)

Promising methods for detection of novel coronavirus SARS-CoV-2. View

Detection of COVID-19: A review of the current literature and future perspectives

Assay Techniques and Test Development for COVID-19 Diagnosis

Diagnostic Testing for Severe Acute Respiratory Syndrome-39

Interpreting Diagnostic Tests for SARS-CoV-2

SalivaDirect: Simple and sensitive molecular diagnostic test for SARS-CoV-2 surveillance. medRxiv

A community-deployable SARS-CoV-2 screening test using raw saliva with 45 minutes sample-to-results turnaround. medRxiv

ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens

Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients

Highly accurate and sensitive diagnostic detection of SARS-CoV-2 by digital

SARS-CoV-2 detection using digital PCR for COVID-19 diagnosis, treatment monitoring and criteria for discharge

Food and Drug Administration

Digital PCR-An Emerging Technology with Broad Applications in Microbiology

Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP. medRxiv

SARS-CoV-2 Detection Using an Isothermal Amplification Reaction and a Rapid, Inexpensive Protocol for Sample Inactivation and Purification. medRxiv

Development of a reverse transcription-loop-mediated isothermal 55

Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19

Loop-mediated isothermal amplification (LAMP): An advanced molecular point-of-care technique for the detection of Leishmania infection. PLoS neglected tropical diseases

DNA nanoscaffold-based SARS-CoV-2 detection for COVID-19 diagnosis

Homogeneous circle-to-circle amplification for real-time optomagnetic detection of SARS-CoV-2 RdRp coding sequence

CRISPR/Cas Systems towards Next-Generation Biosensing

CRISPR-Cas12-based detection of SARS-CoV-2

Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis

Field-deployable viral diagnostics using CRISPR-Cas13. Science

CRISPR-based surveillance for COVID-19 using genomically-comprehensive machine learning design

All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus

SARS-CoV-2 detection with CRISPR diagnostics

Point-of-care Detection of SARS-CoV-2 and Other Respiratory Viruses

Amplicon based MinION sequencing of SARS-CoV-2 and metagenomic characterisation of nasopharyngeal swabs from patients with COVID-19. medRxiv

LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing

Roll-out of 2 new rapid coronavirus tests ahead of winter

A Highly Scalable and Rapidly Deployable RNA Extraction-Free COVID-19 Assay by Quantitative Sanger Sequencing. bioRxiv

A rapid, low cost, and highly sensitive SARS-CoV-2 diagnostic based on whole genome sequencing

Highly multiplexed oligonucleotide probe-ligation testing enables efficient extraction-free SARS-CoV-2 detection and viral genotyping. bioRxiv

Rapid cost-effective viral genome sequencing by V-seq. bioRxiv

Localized surface plasmon resonance sensors

Localized surface plasmon resonance: nanostructures, bioassays and biosensing-a review

Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection

Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles

Developing antibody tests for SARS-CoV-2. The Lancet

Rapid and Sensitive Detection of anti-SARS-CoV-2 IgG, Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay

Development of a Sensitive Immunochromatographic Method Using Lanthanide Fluorescent Microsphere for Rapid Serodiagnosis of COVID-19

Rapid Detection of IgM Antibodies against the SARS-CoV-2 Virus via

SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents

Test performance evaluation of SARS-CoV-2 serological assays. medRxiv

Double-Edged Spike: Are SARS-CoV-2 Serologic Tests Safe Right Now?

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho. medRxiv

Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics

Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience

Performance verification of detecting COVID-19 specific antibody by using four chemiluminescence immunoassay systems. medRxiv

Review-Field-Effect Transistor Biosensing: Devices and Clinical Applications

Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in

Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein

Responding to Covid-19 -A Once-in-a-Century Pandemic?

Temporal dynamics in viral shedding and transmissibility of COVID-19

The authors thank the support from the Department of Biomedical Engineering at Shenzhen University. This work was supported by the Natural Science